Nuvation Bio Inc. (NUVB)
NYQ · Healthcare · Biotechnology
$6.07
-3.34%
Closing price as of 2026-09-11 · Source: TEK2day Finance
Key Metrics
Market Cap
$2.13B
Shares Outstanding
350.1M
P/S (TTM)
12.5x
Exchange
NYQ
Currency
USD
About Nuvation Bio Inc.
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company's lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. It is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 3 clinical trials for the maintenance treatment of high-risk or high-grade IDH1-mutant astrocytoma with safusidenib against placebo. The company was founded in 2018 and is headquartered in New York, New York.
Quarterly Financials
| Metric | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|
| Revenue | 13.1M | 41.9M | 83.2M | 31.7M |
| Gross Profit | 9.8M | 40.6M | 77.2M | 22.2M |
| Operating Income | (56.4M) | (34.0M) | 3.9M | (51.0M) |
| Net Income | (55.8M) | (36.6M) | 5.4M | (62.8M) |
| Diluted EPS | $-0.16 | $-0.11 | $0.01 | $-0.18 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 7.9M | 62.9M |
| Gross Profit | 0.00 | 795K | 53.6M | |
| Operating Income | (119.7M) | (99.8M) | (167.6M) | (213.1M) |
| Net Income | (104.2M) | (75.8M) | (567.9M) | (204.6M) |
| Diluted EPS | $-0.48 | $-0.35 | $-2.11 | N/A |